Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica

Journal of Neuroimmunology

Volumn 263, Issue 1-2, 2013, Pages 148-151

  Shimizu, Yuko ^a   Ota, Kohei ^b   Ikeguchi, Ryotaro ^a   Kubo, Sachiko ^a   Kabasawa, Chiaki ^a   Uchiyama, Shinichiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Disease activity; Disease progression; Multiple sclerosis; Neuromyelitis optica; Plasma osteopontin

Indexed keywords

BETA INTERFERON; OSTEOPONTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMAN CELL; JAPANESE; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

DISEASE ACTIVITY; DISEASE PROGRESSION; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PLASMA OSTEOPONTIN;

ADULT; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; OSTEOPONTIN; YOUNG ADULT;

EID: 84884813611     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.07.005     Document Type: Article

References (27)

1. Ashkar S., et al. Eta-1(osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287:860-864.
2. Bennett J.L., et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66:617-629.
3. Bradl M., et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
4. Chabas D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
5. Chowdhury S.A., Lin J., et al. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch. Neurol. 2008, 65:232-235.
6. Comabella M., et al. Plasma osteopontin levels in multiple sclerosis. J. Immunol. 2005, 158:231-239.
7. Hong J., Hutton G.J. Regulatory effects of interferon-βon osteopontin and interleukin-17 expression in multiple sclerosis. J. Interferon Cytokine Res. 2010, 30:751-757.
8. Inomata S., et al. Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine 2005, 30:203-211.
9. Jansson M., et al. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 2002, 168:2096-2099.
10. Kadota K., et al. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir. Med. 2005, 99:111-117.
11. Kinoshita M., et al. Astrocytic necrosis is induced by anti-aqaporin-4 antibody-positive serum. Neurol. Rep. 2009, 20:508-512.
12. Koguchi Y., et al. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 helper cell response in tuberculosis. Am. J. Respir. Crit. Care Med. 2004, 167:1355-1359.
13. Mazzali M., et al. Osteopontin-a molecule for all seasons. QJM 2002, 95:3-13.
14. Misu T., et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1194-1205.
15. Murugaiyan G., et al. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J. Immunol. 2008, 181:7480-7488.
16. O'Regan A.W. The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 2003, 14:479-488.
17. O'Regan R., Berman J.S. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 2000, 81:373-390.
18. Papandopoulos M.S., Verkman A.S. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012, 11:535-544.
19. Patarca R., et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J. Exp. Med. 1989, 170:145-1611.
20. Sato J., et al. Neuromyelitis optica/Devic's disease: Gene expression profiling of brain lesions. Neuropathology 2008, 28:561-576.
21. Sinclair C., et al. Up-regulation of osteopontin and aBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol. Appl. Neurobiol. 2005, 31:292-303.
22. Steinman L. Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN. Eur. J. Immunol. 2009, 39:2358-2360.
23. Steinman L., Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat. Rev. Immunol. 2003, 3:483-493.
24. Takahashi T., et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J. Exp. Med. 2006, 210:307-313.
25. Vogt M.H.J., et al. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult. Scler. 2010, 16:443-449.
26. Weiss J.M., et al. Osteopontin is involves in initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J. Exp. Med. 2001, 194:1219-1229.
27. Wingerchuk D.M., et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.